RxDoctor Payments Data

Sadia Shah, DPM

Foot & Ankle Surgery · Bronx, NYNPI 1750518130

Payments from drug & device makers

$3,037in general payments, 2019–2025

Across 53 payments — averaging $57.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$380
  • Orthofix Medical, Inc.$324
  • Stryker$223
  • KCI USA, Inc.$212
  • Globus Medical$170
  • Musculoskeletal Transplant Foundation Inc.$170
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$3,037100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,037 in reported general payments places this provider in the 55th percentile of 652 foot & ankle surgery providers in New York.

See all foot & ankle surgery providers in New York

Medicare billing

Part B allowed, 2024
$110,037
Medicare patients
555
Services billed
1,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JubliaEfinaconazole481$718,933
ErtaczoSertaconazole Nitrate182$254,229
Diclofenac Epolamine336$224,556
Diclofenac Potassium98$163,951
Diflorasone Diacetate202$124,810
Halcinonide93$84,569
Diclofenac Sodium722$52,965
Ketoconazole1,603$51,475
Ammonium Lactate1,780$50,080
Oxiconazole Nitrate130$47,276
Doxepin Hcl131$45,016
Ciclopirox1,136$39,492
Clobetasol Propionate260$36,051
AmantadineAmantadine Hcl114$22,357
Clotrimazole579$20,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Kowa Pharmaceuticals America, Inc.Seglentis$163$2,72812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 652 foot & ankle surgery providers in New York.

Other foot & ankle surgery in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →